cCAM Biotherapeutics
Qiryat Shmona
About cCAM Biotherapeutics
cCAM Biotherapeutics is a pre-clinical stage company developing immunotherapies for cancer. cCAM's lead agent, CM-10, is an immunomodulatory antibody that harnesses the patient's immune system to attack tumors. CM-10 binds CEACAM1, a protein used by cancer cells to suppress the immune system. CM-10 abrogates this effect, leading to a cancer specific immune response in patients.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Funding stage: M&A
- Last round: Series A (Sep 2012)
- Website: ccam-bio.com
- Phone: 972 4 681 8829
Industries & Categories
Biotechnology, Clinical Trials, Therapeutics
Canonical: https://fsome.com/organization/ccam-biotherapeutics-2951869 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.